Systemic AA amyloidosis secondary to rheumatoid arthritis may be treatable but is still difficult to manage in daily clinical practice

被引:3
作者
Nakamura, Tadashi [1 ,2 ]
Shiraishi, Naoki [3 ]
Morikami, Yasuhiro [4 ]
Fujii, Hiromi [4 ]
Kuratsu, Junichi [5 ]
机构
[1] Kumamoto Univ, Sect Rheumatol, Kumamoto, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Kumamoto, Japan
[3] Kumamoto Univ, Dept Nephrol, Kumamoto, Japan
[4] Kumamoto Univ, Dept Cardiol, Kumamoto, Japan
[5] Sakurajyuji Hosp, Dept Neurosurg, Kumamoto, Japan
来源
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2019年 / 26卷
关键词
D O I
10.1080/13506129.2019.1582025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
引用
收藏
页码:123 / 124
页数:2
相关论文
共 3 条
  • [1] Nakamura T, 2014, CLIN EXP RHEUMATOL, V32, P501
  • [2] Nakamura T, 2011, CLIN EXP RHEUMATOL, V29, P850
  • [3] Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis
    Nakamura, Tadashi
    Higashi, Syu-ichi
    Tomoda, Kunihiko
    Tsukano, Michishi
    Shono, Masahiro
    [J]. RHEUMATOLOGY, 2012, 51 (11) : 2064 - 2069